A number of other research analysts have also recently issued reports on the company. HC Wainwright reissued a buy rating and set a $17.00 price objective on shares of Iterum Therapeutics in a report on Thursday, August 15th. Royal Bank of Canada cut their price objective on Iterum Therapeutics to $17.00 and set an outperform rating for the company in a report on Wednesday, May 15th. Finally, Zacks Investment Research raised Iterum Therapeutics from a sell rating to a hold rating in a report on Wednesday, July 17th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Iterum Therapeutics has a consensus rating of Buy and a consensus target price of $15.75.
Shares of NASDAQ ITRM opened at $6.41 on Wednesday. The business has a fifty day moving average of $6.65 and a two-hundred day moving average of $6.85. Iterum Therapeutics has a 52-week low of $4.70 and a 52-week high of $11.22. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.10 and a quick ratio of 2.10.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Further Reading: Why do analysts give a neutral rating?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.